摘要
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin's lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neuro-toxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton's tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/ CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.
学科与关键词
- CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System LymphomaLiu, Rui; Cheng, Qian; Kang, Liqing; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Zhang, Yi; Chu, Ling; Chen, Xin; Zhang, Chang; Tan, Jingwen; Xu, Nan; Li, Minghao; Yu, Lei; Li, Xin*Human Gene Therapy, 2022, 33(5-6): 318-329.被引 9
- Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective AnalysisWu, Shaojie; Tu, Sanfang; Zhou, Zhenjun; Sun, Xinlin; Wu, Anqin; Wang, Lei; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib useChen, Feili; Pang, Diwen; Guo, Hanguo; Ou, Qiuxiang; Wu, Xue; Jiang, Xinmiao; Wei, Xiaojuan; Liu, Sichu; Huang, Ling; Liang, Zhanli; Zhou, Dong*; Li, Wenyu*Cancer Medicine, 2020, 9(22): 8676-8684.被引 21
